Ascendis Pharma A/S (NASDAQ:ASND) Receives $191.77 Consensus PT from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $191.77.

ASND has been the subject of several research analyst reports. TD Cowen decreased their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Stifel Nicolaus lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Wedbush restated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Citigroup lifted their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th.

Ascendis Pharma A/S Stock Down 1.0 %

Ascendis Pharma A/S stock opened at $136.38 on Friday. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The company’s 50 day moving average price is $129.69 and its two-hundred day moving average price is $132.81. The stock has a market cap of $8.27 billion, a P/E ratio of -16.88 and a beta of 0.67.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Exome Asset Management LLC increased its stake in shares of Ascendis Pharma A/S by 119.2% in the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock worth $6,547,000 after buying an additional 23,849 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S in the 3rd quarter worth $30,000. Frazier Life Sciences Management L.P. bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $19,908,000. Public Employees Retirement System of Ohio bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $1,101,000. Finally, Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.